Bellicum Pharmaceuticals Inc (BLCM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bellicum Pharmaceuticals Inc (BLCM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7999
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, which is engaged in developing cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products for the treatment of solid tumors, hematological cancers and others. Bellicum is headquartered in Houston, Texas, the US.

Bellicum Pharmaceuticals Inc (BLCM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bellicum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Bellicum Pharmaceuticals Secures USD94.36 Million in Series C Round of Funding 13
Bellicum Pharma Raises USD55 Million In Series C Financing 15
Bellicum Pharma Raises US$14.7 Million In Extended Series B Financing 17
Bellicum Pharma Raises US$20 Million In Series B Financing 18
Partnerships 19
Kiromic Enters into Agreement with Bellicum Pharma 19
Adaptimmune Therapeutics Enters into Co-development Agreement with Bellicum Pharma 20
Bellicum Pharma Enters into Co-Development Agreement with Ospedale Pediatrico Bambino Gesu 21
Bellicum Pharma Enters into Research Agreement with Leiden University Medical Center 22
Licensing Agreements 23
Bellicum Pharmaceuticals Enters Into Licensing Agreement with Baylor College of Medicine 23
Bellicum Pharma Enters into Licensing Agreements with Baylor College of Medicine 24
Bellicum Pharma Enters into Licensing Agreement with Agensys 25
Bellicum Pharma Enters into License Agreement with Biovec Pharma 26
Bellicum Pharma Enters into Licensing Agreement with Leiden University Medical Center 27
Bellicum Pharma Enters into Licensing Agreement with Baylor College of Medicine 29
Equity Offering 30
Bellicum Pharma to Raise up to USD60 Million in Public Offering of Shares 30
Bellicum Pharma Raises USD69 Million in Public Offering of Shares 31
Bellicum Pharma Plans to Raise up to USD63.7 Million in Public Offering of Shares 33
Bellicum Pharma Raises USD69 Million in Public Offering of Shares 34
Bellicum Pharma Raises USD160.6 Million in IPO 36
Bellicum Pharmaceuticals Inc – Key Competitors 38
Bellicum Pharmaceuticals Inc – Key Employees 39
Bellicum Pharmaceuticals Inc – Locations And Subsidiaries 40
Head Office 40
Recent Developments 41
Financial Announcements 41
Aug 07, 2018: Bellicum Pharmaceuticals reports second quarter 2018 financial results 41
May 08, 2018: Bellicum Pharmaceuticals Announces First Quarter 2018 Financial Results 43
Mar 13, 2018: Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017 45
Nov 07, 2017: Bellicum Reports Third Quarter 2017 Financial Results 47
Aug 08, 2017: Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 49
May 08, 2017: Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results 51
Mar 13, 2017: Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 53
Corporate Communications 55
Jul 16, 2018: Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer 55
Feb 21, 2018: Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors 56
Feb 05, 2018: Bellicum Pharmaceuticals Names Dr. William Grossman as Chief Medical Officer 57
Aug 03, 2017: Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer 58
May 15, 2017: Bellicum Pharmaceuticals Announces Management Changes 59
Jan 31, 2017: Bellicum Pharmaceuticals appoints president, CEO and board member 60
Product News 61
02/22/2017: Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers 61
01/31/2017: Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth 62
Product Approvals 63
Jan 30, 2018: Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States 63
Clinical Trials 64
Feb 21, 2017: Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellicum Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Bellicum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bellicum Pharmaceuticals Secures USD94.36 Million in Series C Round of Funding 13
Bellicum Pharma Raises USD55 Million In Series C Financing 15
Bellicum Pharma Raises US$14.7 Million In Extended Series B Financing 17
Bellicum Pharma Raises US$20 Million In Series B Financing 18
Kiromic Enters into Agreement with Bellicum Pharma 19
Adaptimmune Therapeutics Enters into Co-development Agreement with Bellicum Pharma 20
Bellicum Pharma Enters into Co-Development Agreement with Ospedale Pediatrico Bambino Gesu 21
Bellicum Pharma Enters into Research Agreement with Leiden University Medical Center 22
Bellicum Pharmaceuticals Enters Into Licensing Agreement with Baylor College of Medicine 23
Bellicum Pharma Enters into Licensing Agreements with Baylor College of Medicine 24
Bellicum Pharma Enters into Licensing Agreement with Agensys 25
Bellicum Pharma Enters into License Agreement with Biovec Pharma 26
Bellicum Pharma Enters into Licensing Agreement with Leiden University Medical Center 27
Bellicum Pharma Enters into Licensing Agreement with Baylor College of Medicine 29
Bellicum Pharma to Raise up to USD60 Million in Public Offering of Shares 30
Bellicum Pharma Raises USD69 Million in Public Offering of Shares 31
Bellicum Pharma Plans to Raise up to USD63.7 Million in Public Offering of Shares 33
Bellicum Pharma Raises USD69 Million in Public Offering of Shares 34
Bellicum Pharma Raises USD160.6 Million in IPO 36
Bellicum Pharmaceuticals Inc, Key Competitors 38
Bellicum Pharmaceuticals Inc, Key Employees 39

List of Figures
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bellicum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Bellicum Pharmaceuticals Inc (BLCM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Solstad Offshore ASA (SOFF):企業の財務・戦略的SWOT分析
    Summary Solstad Offshore ASA (Solstad) formerly Solstad Farstad ASA is an oil and gas company that provides vessel operation solutions. The company offers carbon footprint, climate neutral network, offshore shipping, green operations, and rainforest protection, documentation programs. It operates th …
  • National Bank Of Kuwait Sak:企業の戦略・SWOT・財務分析
    National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Metsa Board Corporation:企業のM&A・事業提携・投資動向
    Metsa Board Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Metsa Board Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Pedernales Electric Cooperative Inc:企業の戦略的SWOT分析
    Pedernales Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Phillips 66 Co (PSX):企業の財務・戦略的SWOT分析
    Phillips 66 Co (PSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Atrium Innovations Inc-製薬・医療分野:企業M&A・提携分析
    Summary Atrium Innovations Inc (Atrium) is a provider of science-based natural health products. The company develops, manufactures and markets nutritional and dietary supplements. Its major products include minerals, vitamins and specialized products such as enzymes and probiotics. Atrium markets it …
  • Caltex Australia Ltd (CTX)-石油・ガス分野:企業M&A・提携分析
    Summary Caltex Australia Limited (Caltex) is a transport fuel supplier and convenience retailer. It is the parent company of Caltex group. The company purchases, refines, distributes and markets petroleum products. It owns and operates refinery, convenience stores, road tankers, storage terminals, s …
  • MAB Discovery GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary MAB Discovery GmbH (MAB Discovery) is a drug discovery and development company that offers novel antibody therapeutics. The company produces monoclonal antibodies derived from rabbits and rats by employing biochemical and cellular based screens. It relies on natural immune response and B cel …
  • Exorka GmbH:企業の戦略的SWOT分析
    Exorka GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • LSG Sky Chefs Group:企業の戦略・SWOT・財務情報
    LSG Sky Chefs Group - Strategy, SWOT and Corporate Finance Report Summary LSG Sky Chefs Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bracket Global LLC-製薬・医療分野:企業M&A・提携分析
    Summary Bracket Global LLC (Bracket Global) is pharmaceutical company that offers clinical research development services. It strives to bring together science, technology and service to provide superior clinical outcomes for pharmaceutical companies and patients. The company offers services such as …
  • Alabama Municipal Electric Authority:電力:M&Aディール及び事業提携情報
    Summary Alabama Municipal Electric Authority (AMEA) is a not-for-profit publicly-owned electric utility that generates, procures, and supplies power. The authority generates electricity from sources such as gas and solar. AMEA procures electricity from open market and South Carolina Public Service A …
  • The Scoular Company:戦略・SWOT・企業財務分析
    The Scoular Company - Strategy, SWOT and Corporate Finance Report Summary The Scoular Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Xenetic Biosciences Inc (XBIO)-製薬・医療分野:企業M&A・提携分析
    Summary Xenetic Biosciences Inc (Xenetic), formerly General Sales & Leasing, Inc., is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of biologic drugs and innovative orphan cancer drugs. The company’s pipeline products include ErepoXen, Virexxa and OncoHis …
  • Mendor Oy-医療機器分野:企業M&A・提携分析
    Summary Mendor Oy (Mendor) is a medical equipment company that designs, develops and markets advanced diabetes management products. The company’s products include portable blood glucose meter and web-based software application for the daily management of diabetes. It offers blood glucose meter mendo …
  • Ophir Energy Plc (OPHR):石油・ガス:M&Aディール及び事業提携情報
    Summary Ophir Energy Plc (Ophir) is an independent upstream oil and gas company, which explores for and develops oil and gas properties. The company has working interests in assets across Africa and Asia. Ophir has assets in Tanzania, Equatorial Guinea, Kenya, Cote d’Ivoire, and Gabon in Africa; and …
  • The Royal Bank of Scotland Group Plc:企業のM&A・事業提携・投資動向
    The Royal Bank of Scotland Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Royal Bank of Scotland Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • FUJIFILM Holdings Corporation:企業の戦略・SWOT・財務分析
    FUJIFILM Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary FUJIFILM Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Mechanics Bank:企業の戦略・SWOT・財務情報
    Mechanics Bank - Strategy, SWOT and Corporate Finance Report Summary Mechanics Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • SBA Communications Corp (SBAC):企業の財務・戦略的SWOT分析
    Summary SBA Communications Corp (SBA) operates as a wireless communication infrastructure company . The company offers site leasing and site development services. It provides infrastructure solution such as towers, distributed antenna systems (DAS), buildings, rooftops and small cells. The company p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆